Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Preventive Strategies and Novel Treatments for Rheumatoid Arthritis
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Preventive Strategies and Novel Treatments for Rheumatoid Arthritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology & Rheumatology".

Deadline for manuscript submissions: closed (20 July 2026) | Viewed by 853

Editor

Prof. Dr. Vincent Goeb

E-Mail Website
Guest Editor
Rheumatology Department, University Hospital of Amiens, University of Picardie-Jules Verne, Amiens, France
Interests: rheumatoid arthritis; biomarkers; biologics; ankylosing spondylitis; robot-assisted biopsy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Rheumatoid arthritis (RA) is the most common inflammatory and autoimmune rheumatic disease in adults. The reasons for its outbreak in genetically predisposed individuals living in an environment conducive to its development, sometimes occurring following a physical and/or psychological traumatic shock, are still poorly understood, which gives it a continuing status as a topical and fascinating disease. The various patient management strategies are optimized each year. They now allow, after a rapid and accurate diagnosis, for the development of adapted and stratified treatments according to the activity of the disease, the patient profile, and, in particular, their comorbidities. The contribution of increasingly innovative medications is an opportunity, even if we must remain vigilant regarding their safety and tolerance profile in the medium and long term. The clinical presentation of RA has evolved over several years with less destructive forms at the structural level. Clinicians’ daily interest has therefore focused on certain extra-articular manifestations, such as rheumatoid lung disease, and on the management of various comorbidities, such as cardiovascular risk, which still significantly impacts the life expectancy of our patients. This Special Issue, “Preventive Strategies and Novel Treatments for Rheumatoid Arthritis”, is now open to your contributions. We eagerly and kindly await your work on RA, your diagnostic innovations (biomarkers, imaging, etc.), and your therapeutic strategies, as well as your feedback on the various treatments available. We look forward to hearing from you!

Prof. Dr. Vincent Goeb
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatoid arthritis
  • antibodies
  • biologics
  • JAK
  • environment
  • susceptibility
  • therapeutic strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 507 KB  
Article
Relevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective Single-Center Study
by Marie Doussiere, Clémence Jouret, Lara Awad, Pierre-Antoine Bruy, Laetitia Diep, Claire Jesson, Jean-Marc Sobhy-Danial, Franck Grados, Patrice Fardellone and Vincent Goëb
J. Clin. Med. 2026, 15(12), 4631; https://doi.org/10.3390/jcm15124631 - 15 Jun 2026
Viewed by 342
Abstract
Background: Systematic infectious screening is recommended before initiation of biologic therapies in chronic inflammatory rheumatic diseases (CIRDs), yet the clinical impact of this strategy in low-prevalence settings remains insufficiently characterized. This study aimed to evaluate the proportion of abnormal findings and their impact [...] Read more.
Background: Systematic infectious screening is recommended before initiation of biologic therapies in chronic inflammatory rheumatic diseases (CIRDs), yet the clinical impact of this strategy in low-prevalence settings remains insufficiently characterized. This study aimed to evaluate the proportion of abnormal findings and their impact on treatment management. Methods: We conducted a retrospective single-center study including adult patients with CIRDs who underwent systematic pre-biologic infectious screening between January 2019 and June 2025. Screening included HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), interferon-γ release assay (IGRA), and chest radiography. The primary outcome was the proportion of abnormal results and their impact on biologic initiation. Results: A total of 418 patients was included (mean age 48.2 ± 14.6 years; 69.1% female). No active HIV, HBV, or HCV infections were detected. Past HBV infection markers were identified in 2.6% of patients, and anti-HCV antibodies in 0.7%, all without detectable viremia. None of these findings required modification of biologic therapy. IGRA positivity was observed in 4.3% of patients and indeterminate results were seen in 3.1%. Preventive antituberculous therapy was initiated in most newly identified IGRA-positive cases, leading to delayed biologic initiation in several patients. Chest radiography yielded limited additional diagnostic value. Conclusions: In this population, systematic pre-biologic infectious screening identified few clinically actionable viral infections, whereas latent tuberculosis screening represented the main determinant of therapeutic modification. These findings support continued emphasis on tuberculosis risk assessment and warrant further prospective studies to evaluate optimized and potentially targeted screening strategies incorporating cost-effectiveness analyses. Full article
(This article belongs to the Special Issue Preventive Strategies and Novel Treatments for Rheumatoid Arthritis)
►▼ Show Figures

Figure 1

Review

Jump to: Research

26 pages, 1181 KB  
Review
Effect of JAK Inhibitors on Fatigue and Sleep Quality in Patients with Rheumatoid Arthritis: A Narrative Review
by Aleksandra Kowalska, Aleksandra Borkowska, Aleksandra Jawoszek, Grzegorz Chmielewski, Łukasz Jaśkiewicz and Magdalena Krajewska-Włodarczyk
J. Clin. Med. 2026, 15(17), 6559; https://doi.org/10.3390/jcm15176559 - 25 Aug 2026
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease in which fatigue and sleep disturbances, in addition to articular symptoms, are of significant importance. These symptoms are among the most common and burdensome complaints reported by patients; they affect their daily functioning and quality [...] Read more.
Rheumatoid arthritis (RA) is a chronic autoimmune disease in which fatigue and sleep disturbances, in addition to articular symptoms, are of significant importance. These symptoms are among the most common and burdensome complaints reported by patients; they affect their daily functioning and quality of life, and can also exacerbate one another. Currently, the treatment of RA focuses not only on reducing inflammatory activity and preventing structural damage, but also on improving outcomes that matter most to patients. In modern RA treatment, Janus kinase inhibitors (JAKis) are becoming increasingly important; by inhibiting the JAK/STAT pathway, they limit the activity of cytokines involved in the inflammatory response. This review aimed to analyse the effect of selected JAKis on fatigue and sleep quality in patients with RA. An analysis of available study results showed that baricitinib, filgotinib, tofacitinib and upadacitinib reduce fatigue severity. In many cases, improvement was observed as early as the initial stages of treatment and persisted at later follow-up points. At the same time, the extent of this improvement was not uniform and depended on the drug used, the dose, the patient population, and the assessment method adopted. Some analyses also suggested that this effect may have been partly due to reduced pain and improved disease activity. The data on sleep quality are less extensive, but the results suggest that tofacitinib and upadacitinib may also have a beneficial effect in this regard. With tofacitinib, improvements in sleep quality were observed early, affected multiple sleep domains, and, in some studies, persisted over the long term. For upadacitinib, an improvement in sleep quality appeared to be associated with disease control and remission. The smaller number of studies on sleep quality than on fatigue highlights the need to consider this parameter more thoroughly when assessing the efficacy of JAKi treatment and emphasises the importance of a more holistic approach in clinical practice. Full article
(This article belongs to the Special Issue Preventive Strategies and Novel Treatments for Rheumatoid Arthritis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop